Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 9/2013

01.09.2013 | INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Interstitial Lung Disease in Inflammatory Myopathies: Clinical Phenotypes and Prognosis

verfasst von: Patrick D. W. Kiely, Felix Chua

Erschienen in: Current Rheumatology Reports | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Interstitial lung disease (ILD) is a very important complication of the idiopathic inflammatory myositides (IIM), with a prevalence of approximately 40 %. Characteristic HRCT changes, most commonly NSIP, together with a restrictive ventilatory defect and an associated decline in DLco support the presence of ILD. The strongest risk factors are the presence of the anti-amino-acyl-tRNA synthetases (ARS) and anti-MDA-5 antibodies, but a raised index of suspicion for ILD should also apply to IIM patients of black ethnicity. Overall, the prognosis of ILD in IIM is good; between 50 and 66 % of cases have a stable disease course over a substantial period of time. The remaining proportion will show signs of worsening lung disease within 12 months of diagnosis. Whereas ARS antibodies and black ethnicity have no influence on ILD prognosis, detection of the anti-MDA-5 antibody carries a poor ILD outcome, in which hyperferritinaemia appears to be an important diagnostic and prognostic feature.
Literatur
1.
Mills ES, Mathews WH. Interstitial pneumonitis in dermatomyositis. J Am Med Assoc. 1956;160:1467–70.PubMedCrossRef
2.
Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273–84.PubMedCrossRef
3.
Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum. 1984;14:60–76.PubMedCrossRef
4.
Benbassat J, Gefel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis. Arthritis Rheum. 1985;28:249–55.PubMedCrossRef
5.
Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest. 1974;65:403–7.PubMedCrossRef
6.
Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease: a review of the pulmonary histopathologic findings. Arch Int Med. 1981;141:100–10.CrossRef
7.
Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990;141:727–33.PubMedCrossRef
8.
Marie I, Hatron P, Hachulla E, et al. Pulmonary involvement in polymyositis and dermatomyositis. J Rheumatol. 1998;25:1336–43.PubMed
9.
• Chua F, Higton AM, Colebatch AN, et al. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology. 2012;51:1870–6. Describes the association of ILD with black ethnicity in IIM patients. PubMedCrossRef
10.
Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677–85.PubMedCrossRef
11.
Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.PubMedCrossRef
12.
13.
• Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011;183:788–824. Important consensus statement on Idiopathic Pulmonary Fibrosis, new diagnostic criteria compared to previous statement in 2000. PubMedCrossRef
14.
Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated Interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182–5.PubMedCrossRef
15.
Aduen JF, Zisman DA, Mobin SI, et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc. 2007;82:48–54.PubMed
16.
Morganroth PA, Kreider ME, Okawa J, et al. Interstitial lung disease in classic and skin-predominant dermatomyositis. Arch Dermatol. 2010;146:729–38.PubMedCrossRef
17.
Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63:53–9.PubMedCrossRef
18.
Marie I, Hachulla E, Hatron P, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230–7.PubMed
19.
Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol. 2004;49:235–44.PubMedCrossRef
20.
Chinoy H, Salway F, Fertig N, et al. Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology. 2009;48:591–2.PubMedCrossRef
21.
Akira M, Hara H, Sakatani M. Interstitial Lung Disease in Association with Polymyositis-Dermatomyositis: Long-term Follow-up CT Evaluation in Seven Patients. Radiology. 2010;1999:333–8.
22.
Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology. 2005;44:1282–6.PubMedCrossRef
23.
Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297–301.PubMedCrossRef
24.
Mielnik P, Wiesik-Szewczyk E, Olesinska M, et al. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity. 2006;39:243–7.PubMedCrossRef
25.
La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with a ntisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39:249–53.PubMedCrossRef
26.
Vancsa A, Csipo I, Nemeth J, et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29:989–94.PubMedCrossRef
27.
Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37:100–9.PubMedCrossRef
28.
Gunawardena H, Betteridge ZE, Mc Hugh NJ. Myositis-specific antibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–12.PubMedCrossRef
29.
Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.PubMedCrossRef
30.
• Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49:433–40. Series demonstrating the characteristic phenotype on anti-MDA-5-positive DM patients, compared to anti-MDA-5-negative DM patients. PubMedCrossRef
31.
Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–200.PubMedCrossRef
32.
Cao H, Pan M, Kang Y. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma-differentiation-associated gene 5 antibody. Arthritis Care Res. 2012;64:1602–10.CrossRef
33.
• Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:209–14. Review of the spectrum of novel myositis-specific autoantibodies and their clinical phenotypes. PubMedCrossRef
34.
• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–9. Comparison of the phenotypic differences of patients with anti-MDA-5-associated ILD and anti-synthetase-associated ILD. PubMedCrossRef
35.
Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;33:1361–70.PubMedCrossRef
36.
Kao AH, Lacomis D, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50:209–15.PubMedCrossRef
37.
Hengstman GJD, ter Laak HJ, Vree Egberts WTM, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65:1635–8.PubMedCrossRef
38.
• Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589–97. Association of KL-6 with ILD in patients with PM/DM, and relation to pulmonary function tests; a promising biomarker for use in clinical practice. PubMedCrossRef
39.
Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology. 2000;39:632–6.PubMedCrossRef
40.
Kumanovics G, Minier T, Radics J, et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26:414–20.PubMed
41.
Mortensen OH, Andersen K, Fischer C, et al. Calprotectin is released from human skeletal muscle tissue during exercise. J Physiol. 2008;586(14):3551–62.PubMedCrossRef
42.
Seeliger S, Vogl T, Engels IH, et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. Am J Pathol. 2003;163:947–56.PubMedCrossRef
43.
Korthagen NM, Nagtegaal MM, van Moorsel CHM, et al. MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clin Exp Immunol. 2010;161:342–7.PubMed
44.
Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112:286–97.PubMed
45.
Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453–9.PubMedCrossRef
46.
Krystufkova O, Vallerskog T, Barbasso Helmers S, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68:836–43.PubMedCrossRef
47.
• Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1354–60. Association of hyperferritinaemia with poor prognosis in DM. PubMedCrossRef
48.
Lakhanpal S, Lie JT, Conn DL, Martin WJ. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis. 1987;46:23–9.PubMedCrossRef
49.
Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum. 1988;18:29–37.PubMedCrossRef
50.
Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–43.PubMedCrossRef
51.
Maugars YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263–74.PubMed
52.
Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology. 2002;41:22–6.PubMedCrossRef
53.
Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32:58–64.PubMed
54.
Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233–41.PubMedCrossRef
55.
Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis. Serial high-resolution CT findings and functional correlation. Chest. 2003;123:1096–103.PubMedCrossRef
56.
Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. Am J Roentgenol. 1997;169:83–7.CrossRef
57.
Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125–31.PubMedCrossRef
Metadaten
Titel
Interstitial Lung Disease in Inflammatory Myopathies: Clinical Phenotypes and Prognosis
verfasst von
Patrick D. W. Kiely
Felix Chua
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 9/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0359-6

Weitere Artikel der Ausgabe 9/2013

Current Rheumatology Reports 9/2013 Zur Ausgabe

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Epidemiology of Spondyloarthritis: A Review

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Treg Cells in Rheumatoid Arthritis: An Update

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Top 10 Developments in Lupus Nephritis

VASCULITIS (LR ESPINOZA, SECTION EDITOR)

Ocular Vasculitis

SURGERY AND PERIOPERATIVE CARE (CR MACKENZIE AND SM GOODMAN, SECTION EDITORS)

Cardiovascular Risk in the Rheumatic Disease Patient Undergoing Orthopedic Surgery

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Treatment Challenges in Axial Spondylarthritis and Future Directions

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise